Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer

BACKGROUND: In the SPARTAN study, compared with placebo, apalutamide added to ongoing androgen deprivation therapy significantly prolonged metastasis-free survival (MFS) and time to symptomatic progression in patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). Overa...

Full description

Saved in:

Bibliographic Details
Published in:	Ann Oncol
Main Authors:	Small, E J, Saad, F, Chowdhury, S, Oudard, S, Hadaschik, B A, Graff, J N, Olmos, D, Mainwaring, P N, Lee, J Y, Uemura, H, De Porre, P, Smith, A A, Zhang, K, Lopez-Gitlitz, A, Smith, M R
Format:	Artigo
Language:	Inglês
Published:	Oxford University Press 2019
Subjects:	Original Articles
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6927320/ https://ncbi.nlm.nih.gov/pubmed/31560066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz397
Tags:	Add Tag No Tags, Be the first to tag this record!

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer

Similar Items